LRP‐1 as Target of Broad‐Specific Antivirals: Benefits, Risks and Challenges
Reviews in Medical Virology · 2026-05 · 36 (3)
DOI: 10.1002/rmv.70136 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Reviews in Medical Virology, online erschienen am 14.05.2026. Verfasst von Daniela Isabel Maldonado-Bauzá und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Biology, Biomedical Research. Center for Genetic Engineering and Biotechnology, Havana, Cuba. Hauptthemen laut MEDLINE: Antiviral Agents, Low Density Lipoprotein Receptor-Related Protein-1, Virus Diseases, Host-Pathogen Interactions. Die Arbeit nennt 139 Literaturangaben.
Abstract (Originalsprache)
Low‐density lipoprotein receptor‐related protein 1 (LRP‐1) is a highly pleiotropic protein involved in the regulation of numerous signalling pathways and interacts with more than 70 different ligands, including viral particles. Recent studies have shown that LRP‐1 is the receptor for a spectrum of viruses of great relevance to human and animal health. Rift Valley fever virus (RVFV), Oropouche virus (OROV), Severe fever with thrombocytopaenia syndrome virus (SFTSV), Dengue virus (DENV), Sicilian sandfly fever virus (SFSV), La Crosse virus (LACV), Jamestown Canyon virus (JCV), and Chandipura virus (CHPV) interact with LRP‐1 for their infection in mammalian hosts cells. They are included in the arbovirus group, provoke acute disease with significant health implications and present a high risk of transmission from their endemic regions. Currently, none of these viruses have a specific antiviral or vaccine for the treatment of the disease, therefore the development of an antiviral blocking LRP‐1 functions would have great scope and potential. In this review, we searched for the current evidence of the validation of LRP‐1 as a cellular target for a wide range of RNA genome viruses, highlighting common features of these viruses and the regulation of LRP‐1 mediated intracellular signalling in different cell types. In addition, the advantages of an antiviral using LRP‐1 as molecular target are discussed, along with the risks and challenges involved in blocking its activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Systems Biology, Biomedical Research. Center for Genetic Engineering and Biotechnology, Havana, Cuba.
- China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Yongzhou Zhonggu Biotechnology Co., Ltd. (YZGB), Yongzhou, China.
ORCID-Profile: Daniela Isabel Maldonado-Bauzá, Luis Gabriel González-Lodeiro, Li Wen, Vivian Huerta Galindo
Zitieren
APA
Maldonado-Bauzá, D. I., González-Lodeiro, L. G., Wen, L., & Galindo, V. H. (2026). LRP‐1 as Target of Broad‐Specific Antivirals: Benefits, Risks and Challenges. Reviews in Medical Virology, 36(3). https://doi.org/10.1002/rmv.70136
Vancouver
Maldonado-Bauzá DI, González-Lodeiro LG, Wen L, Galindo VH. LRP‐1 as Target of Broad‐Specific Antivirals: Benefits, Risks and Challenges. Reviews in Medical Virology. 2026;36(3). doi:10.1002/rmv.70136
BibTeX
@article{MaldonadoBauz2026,
author = {Maldonado-Bauzá, Daniela Isabel and González-Lodeiro, Luis Gabriel and Wen, Li and Galindo, Vivian Huerta},
title = {LRP‐1 as Target of Broad‐Specific Antivirals: Benefits, Risks and Challenges},
journal = {Reviews in Medical Virology},
year = {2026},
volume = {36},
number = {3},
doi = {10.1002/rmv.70136}
}
EUVIMED